JPH08502082A - 生体適合性ポリマー結合体 - Google Patents

生体適合性ポリマー結合体

Info

Publication number: JPH08502082A
Authority: JP; Japan
Prior art keywords: collagen; peg; conjugate; polymer; composition
Prior art date: 1992-07-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP6503427A

Other languages

English (en)

Japanese (ja)

Inventor

リー，ウーンザ

ジー．ウォレス，ドナルド

エス．マイケルズ，アラン

エイ．，ジュニアバーンズ，レイモン

フリース，ルイス

デラストロ，フランク

ベンツ，ハンネ

マッカルラフ，キンバリー

ダマニ，ラメシュ

エイ．バーグ，リチャード

Original Assignee

コラーゲンコーポレイション

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-02

Filing date

1993-07-01

Publication date

1996-03-05

1992-07-02 Priority claimed from US07/907,518 external-priority patent/US5324775A/en

1993-07-01 Application filed by コラーゲンコーポレイション filed Critical コラーゲンコーポレイション

1996-03-05 Publication of JPH08502082A publication Critical patent/JPH08502082A/ja

Status Pending legal-status Critical Current

Links

229920000249 biocompatible polymer Polymers 0.000 title description 6
229920001223 polyethylene glycol Polymers 0.000 claims abstract description 209
239000000203 mixture Substances 0.000 claims abstract description 163
239000002202 Polyethylene glycol Substances 0.000 claims abstract description 151
229920005615 natural polymer Polymers 0.000 claims abstract description 74
229920001059 synthetic polymer Polymers 0.000 claims abstract description 49
239000003102 growth factor Substances 0.000 claims abstract description 48
102000004127 Cytokines Human genes 0.000 claims abstract description 42
108090000695 Cytokines Proteins 0.000 claims abstract description 42
239000002245 particle Substances 0.000 claims abstract description 20
239000007787 solid Substances 0.000 claims abstract description 15
230000002163 immunogen Effects 0.000 claims abstract description 14
229920001436 collagen Polymers 0.000 claims description 201
102000008186 Collagen Human genes 0.000 claims description 179
108010035532 Collagen Proteins 0.000 claims description 179
229920000642 polymer Polymers 0.000 claims description 64
230000001588 bifunctional effect Effects 0.000 claims description 58
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 47
238000000034 method Methods 0.000 claims description 38
-1 and GF is Substances 0.000 claims description 31
210000000988 bone and bone Anatomy 0.000 claims description 30
239000011324 bead Substances 0.000 claims description 22
238000004132 cross linking Methods 0.000 claims description 19
210000001519 tissue Anatomy 0.000 claims description 19
229920002674 hyaluronan Polymers 0.000 claims description 17
229960003160 hyaluronic acid Drugs 0.000 claims description 16
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 15
239000011541 reaction mixture Substances 0.000 claims description 15
239000001506 calcium phosphate Substances 0.000 claims description 12
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 12
235000019731 tricalcium phosphate Nutrition 0.000 claims description 11
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 10
102000013373 fibrillar collagen Human genes 0.000 claims description 10
108060002894 fibrillar collagen Proteins 0.000 claims description 10
230000009969 flowable effect Effects 0.000 claims description 10
150000002148 esters Chemical group 0.000 claims description 9
229910052588 hydroxylapatite Inorganic materials 0.000 claims description 9
239000011236 particulate material Substances 0.000 claims description 9
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 9
102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 8
108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 8
238000002156 mixing Methods 0.000 claims description 8
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 8
229940078499 tricalcium phosphate Drugs 0.000 claims description 8
229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 8
238000011065 in-situ storage Methods 0.000 claims description 7
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 6
229920001287 Chondroitin sulfate Polymers 0.000 claims description 6
229940059329 chondroitin sulfate Drugs 0.000 claims description 6
230000007547 defect Effects 0.000 claims description 6
229920001477 hydrophilic polymer Polymers 0.000 claims description 6
229920000045 Dermatan sulfate Polymers 0.000 claims description 5
229920002472 Starch Polymers 0.000 claims description 5
230000002378 acidificating effect Effects 0.000 claims description 5
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims description 5
229940051593 dermatan sulfate Drugs 0.000 claims description 5
239000011521 glass Substances 0.000 claims description 5
150000004676 glycans Chemical class 0.000 claims description 5
229920001282 polysaccharide Polymers 0.000 claims description 5
239000005017 polysaccharide Substances 0.000 claims description 5
HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 claims description 5
229910010271 silicon carbide Inorganic materials 0.000 claims description 5
235000019698 starch Nutrition 0.000 claims description 5
229920002683 Glycosaminoglycan Polymers 0.000 claims description 4
102000014150 Interferons Human genes 0.000 claims description 4
108010050904 Interferons Proteins 0.000 claims description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
239000000017 hydrogel Substances 0.000 claims description 4
239000008107 starch Substances 0.000 claims description 4
102000003390 tumor necrosis factor Human genes 0.000 claims description 4
OFMQLVRLOGHAJI-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 OFMQLVRLOGHAJI-FGHAYEPSSA-N 0.000 claims description 3
102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 3
108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 3
102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 3
108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 3
229920002307 Dextran Polymers 0.000 claims description 3
102000003951 Erythropoietin Human genes 0.000 claims description 3
108090000394 Erythropoietin Proteins 0.000 claims description 3
108010010803 Gelatin Proteins 0.000 claims description 3
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
108010025020 Nerve Growth Factor Proteins 0.000 claims description 3
102000015336 Nerve Growth Factor Human genes 0.000 claims description 3
229940112869 bone morphogenetic protein Drugs 0.000 claims description 3
108010035886 connective tissue-activating peptide Proteins 0.000 claims description 3
229940105423 erythropoietin Drugs 0.000 claims description 3
239000008273 gelatin Substances 0.000 claims description 3
229920000159 gelatin Polymers 0.000 claims description 3
235000019322 gelatine Nutrition 0.000 claims description 3
235000011852 gelatine desserts Nutrition 0.000 claims description 3
229940079322 interferon Drugs 0.000 claims description 3
229940053128 nerve growth factor Drugs 0.000 claims description 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 3
229920002379 silicone rubber Polymers 0.000 claims description 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
108010081589 Becaplermin Proteins 0.000 claims description 2
101800003838 Epidermal growth factor Proteins 0.000 claims description 2
102400001368 Epidermal growth factor Human genes 0.000 claims description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
102000015696 Interleukins Human genes 0.000 claims description 2
108010063738 Interleukins Proteins 0.000 claims description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 2
102000013275 Somatomedins Human genes 0.000 claims description 2
230000003190 augmentative effect Effects 0.000 claims description 2
229920003086 cellulose ether Polymers 0.000 claims description 2
229940116977 epidermal growth factor Drugs 0.000 claims description 2
210000002950 fibroblast Anatomy 0.000 claims description 2
108010000685 platelet-derived growth factor AB Proteins 0.000 claims description 2
239000004945 silicone rubber Substances 0.000 claims description 2
NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 1
101800003265 Beta-thromboglobulin Proteins 0.000 claims 1
229920000858 Cyclodextrin Polymers 0.000 claims 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical group CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
239000005977 Ethylene Substances 0.000 claims 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
102100036154 Platelet basic protein Human genes 0.000 claims 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 1
102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims 1
101800004564 Transforming growth factor alpha Proteins 0.000 claims 1
101800000304 Transforming growth factor beta-2 Proteins 0.000 claims 1
230000010261 cell growth Effects 0.000 claims 1
239000011859 microparticle Substances 0.000 claims 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
229940072041 transforming growth factor beta 2 Drugs 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 45
108090000623 proteins and genes Proteins 0.000 abstract description 25
102000004169 proteins and genes Human genes 0.000 abstract description 24
230000003416 augmentation Effects 0.000 abstract description 18
238000000576 coating method Methods 0.000 abstract description 15
210000004872 soft tissue Anatomy 0.000 abstract description 14
239000011248 coating agent Substances 0.000 abstract description 13
239000012530 fluid Substances 0.000 abstract description 8
239000007788 liquid Substances 0.000 abstract description 7
239000000126 substance Substances 0.000 abstract description 6
239000004615 ingredient Substances 0.000 abstract description 5
238000002347 injection Methods 0.000 abstract description 5
239000007924 injection Substances 0.000 abstract description 5
239000007972 injectable composition Substances 0.000 abstract description 4
241000124008 Mammalia Species 0.000 abstract 1
239000000562 conjugate Substances 0.000 description 142
239000000243 solution Substances 0.000 description 71
239000000463 material Substances 0.000 description 65
239000007943 implant Substances 0.000 description 45
210000000845 cartilage Anatomy 0.000 description 39
238000006243 chemical reaction Methods 0.000 description 28
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 24
239000002953 phosphate buffered saline Substances 0.000 description 24
235000018102 proteins Nutrition 0.000 description 22
241001465754 Metazoa Species 0.000 description 19
229920001427 mPEG Polymers 0.000 description 19
239000004698 Polyethylene Substances 0.000 description 17
238000009472 formulation Methods 0.000 description 17
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 15
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 15
238000002360 preparation method Methods 0.000 description 15
238000011282 treatment Methods 0.000 description 15
150000001875 compounds Chemical group 0.000 description 13
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
238000005259 measurement Methods 0.000 description 12
229920000573 polyethylene Polymers 0.000 description 12
230000008439 repair process Effects 0.000 description 12
230000035882 stress Effects 0.000 description 12
230000007704 transition Effects 0.000 description 12
210000003491 skin Anatomy 0.000 description 11
239000003814 drug Substances 0.000 description 10
239000000499 gel Substances 0.000 description 10
239000008188 pellet Substances 0.000 description 10
238000012360 testing method Methods 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 9
230000000694 effects Effects 0.000 description 9
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 9
108090000765 processed proteins & peptides Proteins 0.000 description 9
239000000047 product Substances 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical class ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
238000000113 differential scanning calorimetry Methods 0.000 description 8
230000007062 hydrolysis Effects 0.000 description 8
238000006460 hydrolysis reaction Methods 0.000 description 8
230000000717 retained effect Effects 0.000 description 8
230000004913 activation Effects 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000000835 fiber Substances 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
230000004962 physiological condition Effects 0.000 description 7
238000002054 transplantation Methods 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
125000003277 amino group Chemical group 0.000 description 6
230000008901 benefit Effects 0.000 description 6
238000001125 extrusion Methods 0.000 description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
238000011534 incubation Methods 0.000 description 6
125000005647 linker group Chemical group 0.000 description 6
239000012528 membrane Substances 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
239000000725 suspension Substances 0.000 description 6
ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
239000004472 Lysine Substances 0.000 description 5
206010033733 Papule Diseases 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
239000002253 acid Substances 0.000 description 5
210000000481 breast Anatomy 0.000 description 5
230000006870 function Effects 0.000 description 5
230000028993 immune response Effects 0.000 description 5
230000001976 improved effect Effects 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
229920001296 polysiloxane Polymers 0.000 description 5
230000004044 response Effects 0.000 description 5
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 4
NWAGXLBTAPTCPR-UHFFFAOYSA-N 5-(2,5-dioxopyrrolidin-1-yl)oxy-5-oxopentanoic acid Chemical compound OC(=O)CCCC(=O)ON1C(=O)CCC1=O NWAGXLBTAPTCPR-UHFFFAOYSA-N 0.000 description 4
206010002329 Aneurysm Diseases 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
239000004971 Cross linker Substances 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
229910000389 calcium phosphate Inorganic materials 0.000 description 4
235000011010 calcium phosphates Nutrition 0.000 description 4
230000008859 change Effects 0.000 description 4
239000000512 collagen gel Substances 0.000 description 4
230000021615 conjugation Effects 0.000 description 4
210000004207 dermis Anatomy 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
238000001035 drying Methods 0.000 description 4
125000001033 ether group Chemical group 0.000 description 4
239000002657 fibrous material Substances 0.000 description 4
VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 4
238000001802 infusion Methods 0.000 description 4
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000035484 reaction time Effects 0.000 description 4
210000005070 sphincter Anatomy 0.000 description 4
239000007858 starting material Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000008467 tissue growth Effects 0.000 description 4
208000010392 Bone Fractures Diseases 0.000 description 3
102000029816 Collagenase Human genes 0.000 description 3
108060005980 Collagenase Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
229920001734 PEG propionaldehyde Polymers 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
102000016611 Proteoglycans Human genes 0.000 description 3
108010067787 Proteoglycans Proteins 0.000 description 3
230000009102 absorption Effects 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
229960002424 collagenase Drugs 0.000 description 3
210000002808 connective tissue Anatomy 0.000 description 3
210000001608 connective tissue cell Anatomy 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
238000007865 diluting Methods 0.000 description 3
238000005538 encapsulation Methods 0.000 description 3
210000003979 eosinophil Anatomy 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012467 final product Substances 0.000 description 3
239000003517 fume Substances 0.000 description 3
JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 3
230000012010 growth Effects 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
230000008595 infiltration Effects 0.000 description 3
238000001764 infiltration Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
244000145841 kine Species 0.000 description 3
238000000465 moulding Methods 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
230000011164 ossification Effects 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
230000000704 physical effect Effects 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000004033 plastic Substances 0.000 description 3
230000000405 serological effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000002002 slurry Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000700198 Cavia Species 0.000 description 2
229920002101 Chitin Polymers 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010015150 Erythema Diseases 0.000 description 2
208000005422 Foreign-Body reaction Diseases 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
229920002971 Heparan sulfate Polymers 0.000 description 2
208000035809 Lymphohistiocytosis Diseases 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
101100293261 Mus musculus Naa15 gene Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000906446 Theraps Species 0.000 description 2
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
150000008065 acid anhydrides Chemical class 0.000 description 2
239000003929 acidic solution Substances 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
239000004020 conductor Substances 0.000 description 2
230000001268 conjugating effect Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 2
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
230000029087 digestion Effects 0.000 description 2
GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000002500 effect on skin Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
210000002615 epidermis Anatomy 0.000 description 2
231100000321 erythema Toxicity 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
239000012456 homogeneous solution Substances 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
230000010354 integration Effects 0.000 description 2
230000001788 irregular Effects 0.000 description 2
210000003041 ligament Anatomy 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000011707 mineral Substances 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000010534 nucleophilic substitution reaction Methods 0.000 description 2
230000002188 osteogenic effect Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
229920001343 polytetrafluoroethylene Polymers 0.000 description 2
239000004810 polytetrafluoroethylene Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000009103 reabsorption Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
238000002791 soaking Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000012421 spiking Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229910052719 titanium Inorganic materials 0.000 description 2
239000010936 titanium Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
230000002792 vascular Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
SWGZHHCRMZDRSN-BTJKTKAUSA-N (Z)-but-2-enedioic acid 1-phenoxypropan-2-ylhydrazine Chemical compound OC(=O)\C=C/C(O)=O.NNC(C)COC1=CC=CC=C1 SWGZHHCRMZDRSN-BTJKTKAUSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
JPSKCQCQZUGWNM-UHFFFAOYSA-N 2,7-Oxepanedione Chemical compound O=C1CCCCC(=O)O1 JPSKCQCQZUGWNM-UHFFFAOYSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
235000018185 Betula X alpestris Nutrition 0.000 description 1
235000018212 Betula X uliginosa Nutrition 0.000 description 1
240000007124 Brassica oleracea Species 0.000 description 1
241001631457 Cannula Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
235000014036 Castanea Nutrition 0.000 description 1
241001070941 Castanea Species 0.000 description 1
208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
241000255925 Diptera Species 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010051814 Eschar Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
241000720950 Gluta Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
238000006957 Michael reaction Methods 0.000 description 1
206010062575 Muscle contracture Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000233855 Orchidaceae Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
208000006735 Periostitis Diseases 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
229920002596 Polyethylene Glycol 900 Polymers 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
ITJLNEXJUADEMK-UHFFFAOYSA-N Shirin Natural products CCC(C)(O)c1c(Cl)c(OC)c(C)c2OC(=O)c3c(C)c(Cl)c(O)c(Cl)c3Oc12 ITJLNEXJUADEMK-UHFFFAOYSA-N 0.000 description 1
241000212342 Sium Species 0.000 description 1
229920002385 Sodium hyaluronate Polymers 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000007605 air drying Methods 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000001195 anabolic effect Effects 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229910052586 apatite Inorganic materials 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000006399 behavior Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
OMAHFYGHUQSIEF-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) oxalate Chemical compound O=C1CCC(=O)N1OC(=O)C(=O)ON1C(=O)CCC1=O OMAHFYGHUQSIEF-UHFFFAOYSA-N 0.000 description 1
OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
238000009954 braiding Methods 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910001576 calcium mineral Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000003763 carbonization Methods 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
231100000481 chemical toxicant Toxicity 0.000 description 1
235000015111 chews Nutrition 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000004581 coalescence Methods 0.000 description 1
239000000501 collagen implant Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000000306 component Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
208000006111 contracture Diseases 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical compound C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000005115 demineralization Methods 0.000 description 1
230000002328 demineralizing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
231100000333 eschar Toxicity 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000009778 extrusion testing Methods 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007306 functionalization reaction Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
238000011597 hartley guinea pig Methods 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
210000001624 hip Anatomy 0.000 description 1
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
229940099552 hyaluronan Drugs 0.000 description 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
230000003832 immune regulation Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000000111 lower esophageal sphincter Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000009607 mammography Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000000921 morphogenic effect Effects 0.000 description 1
HRRDCWDFRIJIQZ-UHFFFAOYSA-N naphthalene-1,8-dicarboxylic acid Chemical compound C1=CC(C(O)=O)=C2C(C(=O)O)=CC=CC2=C1 HRRDCWDFRIJIQZ-UHFFFAOYSA-N 0.000 description 1
YTVNOVQHSGMMOV-UHFFFAOYSA-N naphthalenetetracarboxylic dianhydride Chemical compound C1=CC(C(=O)OC2=O)=C3C2=CC=C2C(=O)OC(=O)C1=C32 YTVNOVQHSGMMOV-UHFFFAOYSA-N 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003921 oil Substances 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000002379 periodontal ligament Anatomy 0.000 description 1
210000003460 periosteum Anatomy 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
150000003017 phosphorus Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000037074 physically active Effects 0.000 description 1
108010017843 platelet-derived growth factor A Proteins 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920005596 polymer binder Polymers 0.000 description 1
239000002491 polymer binding agent Substances 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
239000011856 silicon-based particle Substances 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940010747 sodium hyaluronate Drugs 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
210000004003 subcutaneous fat Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical class O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
238000004381 surface treatment Methods 0.000 description 1
230000008961 swelling Effects 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
239000013076 target substance Substances 0.000 description 1
210000004876 tela submucosa Anatomy 0.000 description 1
239000004753 textile Substances 0.000 description 1
230000009772 tissue formation Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
210000005062 tracheal ring Anatomy 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
238000012546 transfer Methods 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000013191 viscoelastic testing Methods 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
238000009941 weaving Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/102—Collagen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0033—Collagen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/043—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/044—Proteins; Polypeptides; Degradation products thereof
- A61L29/045—Collagen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/044—Collagen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
- C08H1/06—Macromolecular products derived from proteins derived from horn, hoofs, hair, skin or leather
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J189/00—Adhesives based on proteins; Adhesives based on derivatives thereof
- C09J189/04—Products derived from waste materials, e.g. horn, hoof or hair
- C09J189/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2666/00—Composition of polymers characterized by a further compound in the blend, being organic macromolecular compounds, natural resins, waxes or and bituminous materials, non-macromolecular organic substances, inorganic substances or characterized by their function in the composition
- C08L2666/02—Organic macromolecular compounds, natural resins, waxes or and bituminous materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Oral & Maxillofacial Surgery (AREA)
Transplantation (AREA)
Molecular Biology (AREA)
Materials Engineering (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Polymers & Plastics (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Composite Materials (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Materials For Medical Uses (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Polyethers (AREA)
Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

JP6503427A 1992-07-02 1993-07-01 生体適合性ポリマー結合体 Pending JPH08502082A (ja)

Applications Claiming Priority (13)

Application Number	Priority Date	Filing Date	Title
US07/907,518 US5324775A (en)	1988-11-21	1992-07-02	Biologically inert, biocompatible-polymer conjugates
US07/907,518		1992-07-02
US07/922,541		1992-07-30
US07/922,541 US5328955A (en)	1988-11-21	1992-07-30	Collagen-polymer conjugates
US98493392A	1992-12-02	1992-12-02
US07/984,197 US5308889A (en)	1988-11-21	1992-12-02	Dehydrated collagen-polymer strings
US07/984,933		1992-12-02
US07/984,197		1992-12-02
US07/985,680		1992-12-02
US07/985,680 US5292802A (en)	1988-11-21	1992-12-02	Collagen-polymer tubes for use in vascular surgery
US2503293A	1993-03-02	1993-03-02
US08/025,032		1993-03-02
PCT/US1993/006292 WO1994001483A1 (fr)	1992-07-02	1993-07-01	Conjugues polymeres biocompatibles

Publications (1)

Publication Number	Publication Date
JPH08502082A true JPH08502082A (ja)	1996-03-05

Family

ID=27556046

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP6503427A Pending JPH08502082A (ja)	1992-07-02	1993-07-01	生体適合性ポリマー結合体

Country Status (4)

Country	Link
EP (1)	EP0648239A4 (fr)
JP (1)	JPH08502082A (fr)
AU (1)	AU677789B2 (fr)
WO (1)	WO1994001483A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004173941A (ja) *	2002-11-27	2004-06-24	Olympus Corp	カルシウム傾斜材料とその製造方法
JP2004359895A (ja) *	2003-06-06	2004-12-24	Mcrotech Kk	医療用組成物
JP2005272398A (ja) *	2004-03-25	2005-10-06	Shiseido Co Ltd	皮膚のシワを改善する方法及びシワ改善具
JP2007023280A (ja) *	2005-07-12	2007-02-01	Kwangju Inst Of Science & Technol	シクロデキストリンとポリ（オキシエチレン）の結合体、及びその製造方法
WO2007083522A1 (fr) *	2006-01-18	2007-07-26	Next21 K. K.	Composition formant gel a usage medical, dispositifs d'application de la composition et vehicule reglant la liberation de medicament
WO2010070775A1 (fr) *	2008-12-19	2010-06-24	株式会社ネクスト２１	Hydrogel injectable à ultra-haute résistance et procédé de fabrication associé
JP2010528046A (ja) *	2007-05-23	2010-08-19	アラーガン、インコーポレイテッド	架橋コラーゲンおよびその使用
WO2013021836A1 (fr) *	2011-08-05	2013-02-14	公立大学法人大阪市立大学	Hydrogel fonctionnel
JP2015061606A (ja) *	2006-03-29	2015-04-02	インセプトエルエルシー	医療用高吸収性凍結乾燥ヒドロゲル
JPWO2021025005A1 (fr) *	2019-08-05	2021-02-11

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5565519A (en) *	1988-11-21	1996-10-15	Collagen Corporation	Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5643464A (en) *	1988-11-21	1997-07-01	Collagen Corporation	Process for preparing a sterile, dry crosslinking agent
US5936035A (en) *	1988-11-21	1999-08-10	Cohesion Technologies, Inc.	Biocompatible adhesive compositions
US5475052A (en) *	1988-11-21	1995-12-12	Collagen Corporation	Collagen-synthetic polymer matrices prepared using a multiple step reaction
US5510418A (en) *	1988-11-21	1996-04-23	Collagen Corporation	Glycosaminoglycan-synthetic polymer conjugates
SK281042B6 (sk)	1992-09-18	2000-11-07	Yamanouchi Pharmaceutical Co., Ltd	Prípravok hydrogélového typu s ustáleným uvoľňovaním
US5548064A (en) *	1993-05-24	1996-08-20	Biotech Australia Pty Limited	Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
CA2140053C (fr) *	1994-02-09	2000-04-04	Joel S. Rosenblatt	Systeme a base de collagene pour l'administration de drogue injectable, et utilisation
AU1014695A (en) *	1994-02-17	1995-08-24	Collagen Corporation	Collagen-synthetic polymer conjugates having controlled fiber size distributions
JPH10501706A (ja) *	1994-04-04	1998-02-17	コラーゲンコーポレイション	細胞−ゲル
CA2151547C (fr) *	1994-06-10	2010-10-12	Elliott A. Gruskin	Proteines chimeriques recombinantes et modes d'utilisation de ces proteines
EP0713707A1 (fr)	1994-11-23	1996-05-29	Collagen Corporation	Composition de collagène insectable, réticulable in situ pour augmenter des tissus
US6962979B1 (en)	1995-03-14	2005-11-08	Cohesion Technologies, Inc.	Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents
CA2165728A1 (fr) *	1995-03-14	1996-09-15	Woonza M. Rhee	Utilisation d'agents de reticulation hydrophobes pour preparer des compositions de biomatiere reticulee
DE19514087A1 (de) *	1995-04-13	1996-10-17	Deutsches Krebsforsch	Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
PT831882E (pt) *	1995-06-07	2005-01-31	Organogenesis Inc	Composicoes de segmentos de fibra de colagenio reconstituido e metodos de preparacao das mesmas
US5776193A (en)	1995-10-16	1998-07-07	Orquest, Inc.	Bone grafting matrix
JPH09143093A (ja)	1995-11-17	1997-06-03	Hoechst Japan Ltd	軟骨・骨誘導性修復用材料
US5752974A (en) *	1995-12-18	1998-05-19	Collagen Corporation	Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
WO1997022371A1 (fr)	1995-12-18	1997-06-26	Collagen Corporation	Composition a base de polymeres reticules et leur procede d'utilisation
JP2002504083A (ja) *	1996-03-05	2002-02-05	オーケストインコーポレイテッド	ヒアルロン酸および増殖因子による骨の増殖を促進する方法
US5855615A (en) *	1996-06-07	1999-01-05	Menlo Care, Inc.	Controller expansion sphincter augmentation media
TW555765B (en)	1996-07-09	2003-10-01	Amgen Inc	Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6083522A (en) *	1997-01-09	2000-07-04	Neucoll, Inc.	Devices for tissue repair and methods for preparation and use thereof
GB9722604D0 (en) *	1997-10-28	1997-12-24	Cancer Res Campaign Tech	Heparin-binding growth factor derivatives
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
EP1316323A1 (fr) *	1998-12-31	2003-06-04	Angiotech Pharmaceuticals, Inc.	Prothèses endovasculaires à revêtements bioactifs
IL143922A0 (en) *	1998-12-31	2002-04-21	Angiotech Pharm Inc	A stent graft with a bioactive coating
FR2790475B1 (fr)	1999-03-02	2003-01-24	Flamel Tech Sa	Peptides collageniques modifies par greffage de fonctions mercapto, l'un de leurs procedes d'obtention et leurs applications comme biomateriaux
WO2001005434A2 (fr) *	1999-07-20	2001-01-25	Amgen Inc.	Conjugues hyaluroniques acide-proteine, compositions pharmaceutiques et procedes correspondants
US6592794B1 (en)	1999-09-28	2003-07-15	Organogenesis Inc.	Process of making bioengineered collagen fibrils
AU6459299A (en) *	1999-10-29	2001-05-14	Min Hu	Surface treatment with polypeptides to improve fibroblast adhesion to hyaluronan
EP1242008B1 (fr)	1999-12-17	2006-03-08	Cartificial A/S	Dispositif prothetique
SG98393A1 (en)	2000-05-19	2003-09-19	Inst Materials Research & Eng	Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
EP1311657A2 (fr) *	2000-08-21	2003-05-21	Rice University	Production de proteine matricielle d'amelioration de charpentes pour genie tissulaire
AU2002233097A1 (en) *	2002-02-28	2003-09-09	Eidgenossische Technische Hochschule Zurich Oberflachentechnik	Biomedical implant surfaces with osteogenic properties
DE10209821A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung von Proteinen an ein modifiziertes Polysaccharid
US7538092B2 (en)	2002-10-08	2009-05-26	Fresenius Kabi Deutschland Gmbh	Pharmaceutically active oligosaccharide conjugates
AU2003303513A1 (en) *	2002-12-30	2004-07-29	Angiotech International Ag	Tissue reactive compounds and compositions and uses thereof
AU2003300076C1 (en)	2002-12-30	2010-03-04	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
FR2850282B1 (fr)	2003-01-27	2007-04-06	Jerome Asius	Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation
DE10303584A1 (de) *	2003-01-30	2004-08-12	Stauss, Robert, Dr.	Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten
WO2005014655A2 (fr)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugues d'amidon d'hydroxyalkyle et de proteine
US8002830B2 (en)	2004-02-06	2011-08-23	Georgia Tech Research Corporation	Surface directed cellular attachment
AU2005212339B2 (en)	2004-02-06	2010-11-25	Georgia Tech Research Corporation	Load bearing biocompatible device
EP1796602A4 (fr)	2004-09-17	2016-10-19	Angiotech Pharm Inc	Composes multifonctionels pour la formation de biomateriaux reticules et leurs procedes de preparation et d'utilisation
MX2010002448A (es)	2007-08-27	2010-10-04	Biogenerix Ag	Formulacion liquida del g-csf conjugado.
EP2757964B1 (fr)	2011-05-26	2016-05-04	Cartiva, Inc.	Implant d'articulation conique et outils associés
WO2016161026A1 (fr)	2015-03-31	2016-10-06	Cartiva, Inc.	Implants carpométacarpiens (cmc) et procédés
US9907663B2 (en)	2015-03-31	2018-03-06	Cartiva, Inc.	Hydrogel implants with porous materials and methods
WO2016168363A1 (fr)	2015-04-14	2016-10-20	Cartiva, Inc.	Outillage pour création d'une ouverture conique dans le tissu et procédés associés
US20160303281A1 (en) *	2015-04-17	2016-10-20	Rochal Industries, Llc	Composition and kits for pseudoplastic microgel matrices
WO2020226250A1 (fr) *	2019-05-08	2020-11-12	서울대학교병원	Implant médical modifié en surface avec un polypeptide fonctionnel

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3091542A (en) *	1960-09-20	1963-05-28	Dow Chemical Co	Insolubilization of water-soluble cellulose ethers
US3949073A (en) *	1974-11-18	1976-04-06	The Board Of Trustees Of Leland Stanford Junior University	Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution
JPS5896026A (ja) *	1981-10-30	1983-06-07	Nippon Chemiphar Co Ltd	新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4424208A (en) *	1982-01-11	1984-01-03	Collagen Corporation	Collagen implant material and method for augmenting soft tissue
US4487865A (en) *	1983-12-15	1984-12-11	Biomatrix, Inc.	Polymeric articles modified with hyaluronate
US4496689A (en) *	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS643116A (en) *	1987-06-25	1989-01-06	Nippon Oil & Fats Co Ltd	Plaster for patch
US4847325A (en) *	1988-01-20	1989-07-11	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
US5162430A (en) *	1988-11-21	1992-11-10	Collagen Corporation	Collagen-polymer conjugates
JPH06501008A (ja) *	1990-08-30	1994-01-27	ザ　バイオメンブレン　インスティテュート	オリゴ糖あるいはオリゴ糖抗原または抗体による転移能および侵襲性の抑制

1993
- 1993-07-01 AU AU46620/93A patent/AU677789B2/en not_active Ceased
- 1993-07-01 WO PCT/US1993/006292 patent/WO1994001483A1/fr not_active Ceased
- 1993-07-01 EP EP93916926A patent/EP0648239A4/fr not_active Withdrawn
- 1993-07-01 JP JP6503427A patent/JPH08502082A/ja active Pending

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004173941A (ja) *	2002-11-27	2004-06-24	Olympus Corp	カルシウム傾斜材料とその製造方法
JP2004359895A (ja) *	2003-06-06	2004-12-24	Mcrotech Kk	医療用組成物
JP2005272398A (ja) *	2004-03-25	2005-10-06	Shiseido Co Ltd	皮膚のシワを改善する方法及びシワ改善具
JP2007023280A (ja) *	2005-07-12	2007-02-01	Kwangju Inst Of Science & Technol	シクロデキストリンとポリ（オキシエチレン）の結合体、及びその製造方法
WO2007083522A1 (fr) *	2006-01-18	2007-07-26	Next21 K. K.	Composition formant gel a usage medical, dispositifs d'application de la composition et vehicule reglant la liberation de medicament
JPWO2007083522A1 (ja) *	2006-01-18	2009-06-11	株式会社ネクスト２１	医療用ゲル形成組成物，その組成物の投与デバイス及び薬剤放出制御担体
JP2015061606A (ja) *	2006-03-29	2015-04-02	インセプトエルエルシー	医療用高吸収性凍結乾燥ヒドロゲル
JP2010528046A (ja) *	2007-05-23	2010-08-19	アラーガン、インコーポレイテッド	架橋コラーゲンおよびその使用
WO2010070775A1 (fr) *	2008-12-19	2010-06-24	株式会社ネクスト２１	Hydrogel injectable à ultra-haute résistance et procédé de fabrication associé
JPWO2010070775A1 (ja) *	2008-12-19	2012-05-24	株式会社ネクスト２１	超高強度インジェクタブルハイドロゲル及びその製造方法
WO2013021836A1 (fr) *	2011-08-05	2013-02-14	公立大学法人大阪市立大学	Hydrogel fonctionnel
JPWO2013021836A1 (ja) *	2011-08-05	2015-03-05	公立大学法人大阪市立大学	機能性ハイドロゲル
JPWO2021025005A1 (fr) *	2019-08-05	2021-02-11

Also Published As

Publication number	Publication date
AU4662093A (en)	1994-01-31
AU677789B2 (en)	1997-05-08
EP0648239A1 (fr)	1995-04-19
EP0648239A4 (fr)	1995-09-27
WO1994001483A1 (fr)	1994-01-20

Publication	Publication Date	Title
JPH08502082A (ja)	1996-03-05	生体適合性ポリマー結合体
JP2505312B2 (ja)	1996-06-05	コラ―ゲン―ポリマ―結合物
US5523348A (en)	1996-06-04	Method of preparing collagen-polymer conjugates
US5264214A (en)	1993-11-23	Composition for bone repair
US5304595A (en)	1994-04-19	Collagen-polymer conjugates
US6165489A (en)	2000-12-26	Crosslinked collagen compositions for in situ administration
US8957050B2 (en)	2015-02-17	Bone implant materials comprising cross-linked bioactive hydrogel matrices
TWI436793B (zh)	2014-05-11	快速作用之乾密封膠及其使用和製造方法
US10383981B2 (en)	2019-08-20	Structural lattice and method of making same
JPH07278203A (ja)	1995-10-24	グリコサミノグリカン−合成ポリマー結合体
JP2000502380A (ja)	2000-02-29	架橋ポリマー組成物およびその使用方法
JP2006506110A (ja)	2006-02-23	硫酸化多糖及び線維状タンパク質の凝集性共沈殿物及びその使用
EP0668081A2 (fr)	1995-08-23	Conjugués de collagène et de polymères synthétiques présentant des distributions de grosseur de fibres contrôlées
JPH09249751A (ja)	1997-09-22	架橋生体物質組成物を調製するための疎水性架橋剤の使用
JP2008132338A (ja)	2008-06-12	架橋生体物質組成物を調製するための疎水性架橋剤の使用
JP2006181389A (ja)	2006-07-13	架橋生体物質組成物を調製するための疎水性架橋剤の使用